Baird raises DexCom stock to outperform, target to $104
Investing.com -- Baird upgraded DexCom Inc (NASDAQ:DXCM). to "Outperform" from "Neutral," citing progress in U.S. sales and upcoming catalysts. The price target was raised to $104 from $98. DexCom's improved salesforce productivity …